{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:09:27Z","timestamp":1791295767365,"version":"4.1.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"\n Importance<\/jats:title>\n Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options. PrimeC is a fixed-dose oral combination of celecoxib and ciprofloxacin designed to target ALS-related mechanisms, including neuroinflammation, iron homeostasis, and dysregulated microRNAs.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the safety, tolerability, and potential efficacy of PrimeC in people living with ALS.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was a randomized, double-blind, placebo-controlled, phase 2b trial conducted at 4 ALS referral centers from May 2022 to November 2023 and followed by 12-month open-label extension. Adults with definite or probable ALS and disease duration of 30 months or less were eligible. Of 73 screened, 69 were randomized and 68 were included in the intent-to-treat population.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomized 2:1 to receive PrimeC or placebo for 6 months, followed by open-label extension PrimeC for all.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was safety and tolerability. The prespecified primary biomarker outcome was plasma neuron-derived-exosomal TAR DNA-binding protein 43 (TDP-43) or prostaglandinJ2. Secondary outcomes included change in ALS Functional Rating Scale\u2013Revised (ALSFRS-R) score at 6 and 18 months, survival, and time-to-composite events. Exploratory biomarkers included neurofilament light chains, iron-regulatory proteins, and circulating microRNAs.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The 68 participants were well balanced in age at entry and sex. In the PrimeC group, the mean (SD) age was 59.1 (9.1) years, and 27 of 45 participants were male. In the placebo group, the mean (SD) age was 55.0 (13.0) years, and 14 of 23 participants were male. PrimeC was well tolerated, with a safety profile comparable to placebo (adverse event rate, 66.7% PrimeC vs 65.2% placebo). Drug-related adverse events were more frequent with PrimeC (20.0% vs 4.3%), mostly mild to moderate, and transient. At month 6, the mean ALSFRS-R difference was 2.23 points between PrimeC and placebo (95% CI, \u22120.61 to 5.07;\n P<\/jats:italic>\n \u2009=\u2009.12). At month 18, ALSFRS-R scores in participants continuously treated with PrimeC maintained a difference (7.92 points; 95% CI, 2.25 to 13.60;\n P<\/jats:italic>\n \u2009=\u2009.007), with significant bulbar difference (3.18 points; 95% CI, 1.32 to 5.04;\n P<\/jats:italic>\n \u2009=\u2009.001). Continuous treatment was associated with lower risk of ALS complications, including hospitalization, respiratory failure, or death (HR, 0.36; 95% CI, 0.15\u20130.85;\n P<\/jats:italic>\n \u2009=\u2009.02). In the double-blind period, transferrin levels were preserved with PrimeC (1.90 \u03bcmol\/L difference;\n P<\/jats:italic>\n \u2009=\u2009.03), the negative ferritin-ALSFRS-R correlation observed in placebo (\u03c1\u2009=\u2009\u22120.50;\n P<\/jats:italic>\n \u2009=\u2009.02) was abolished, and ALS-associated microRNAs were downregulated (log\n 2<\/jats:sub>\n fold change: miR-199a-3p, \u22121.87; false discovery rate [FDR]\n P<\/jats:italic>\n \u2009=\u2009.004; miR-199a-5p, \u22122.23; FDR\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001; miR-181a-5p: \u22121.89; FDR\n P<\/jats:italic>\n \u2009=\u2009.001; miR-181b-5p, \u22121.62; FDR\n P<\/jats:italic>\n \u2009=\u2009.005). Prespecified neuron-derived exosome TDP-43\/PgJ2 analyses will be reported separately following completion of development and analyses.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n PrimeC was safe and well tolerated over 18 months. Although not powered for efficacy, functional and biomarker findings support a confirmatory trial.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT05357950<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2026.0230","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:30:38Z","timestamp":1773675038000},"page":"471","source":"Crossref","is-referenced-by-count":4,"title":["Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis"],"prefix":"10.1001","volume":"83","author":[{"given":"Merit","family":"Cudkowicz","sequence":"first","affiliation":[{"name":"Healey & AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian E.","family":"Drory","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tel-Aviv Sourasky Medical Centre, Tel Aviv, Israel"},{"name":"Gray Faculty of Medical and Health Science, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Chio","sequence":"additional","affiliation":[{"name":"Rita Levi Montalcini Department of Neuroscience, University of Torino and Azienda Ospedaliero Universitaria Citt\u00e0 della Salute e della Scienza, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lunetta","sequence":"additional","affiliation":[{"name":"Istituti Clinici Scientifici Maugeri IRCCS, Neurorehabilitation Department, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christen","family":"Shoesmith","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurological Sciences, Division of Neurology, London Health Sciences Centre, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben P. A.","family":"van Eijk","sequence":"additional","affiliation":[{"name":"Department of Neurology and Biostatistics, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiran","family":"Salomon-Zimri","sequence":"additional","affiliation":[{"name":"NeuroSense Therapeutics, Herzliya, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Shtossel","sequence":"additional","affiliation":[{"name":"NeuroSense Therapeutics, Herzliya, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitai","family":"Kerem","sequence":"additional","affiliation":[{"name":"NeuroSense Therapeutics, Herzliya, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Shapira","sequence":"additional","affiliation":[{"name":"Gray Faculty of Medical and Health Science, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Shomron","sequence":"additional","affiliation":[{"name":"Gray Faculty of Medical and Health Science, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niva","family":"Russek-Blum","sequence":"additional","affiliation":[{"name":"NeuroSense Therapeutics, Herzliya, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc","family":"Tracik","sequence":"additional","affiliation":[{"name":"NeuroSense Therapeutics, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Rosenfeld","sequence":"additional","affiliation":[{"name":"Department of Neurology, Loma Linda University School of Medicine, Loma Linda, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Shefner","sequence":"additional","affiliation":[{"name":"Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"16","key":"noi260007r1","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1056\/NEJMc1710379","article-title":"Amyotrophic lateral sclerosis.","volume":"377","author":"Brown","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"noi260007r2","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3390\/cells12111523","article-title":"Current state and future directions in the therapy of ALS.","volume":"12","author":"Tzeplaeff","year":"2023","journal-title":"Cells"},{"issue":"29","key":"noi260007r3","doi-asserted-by":"publisher","first-page":"13111","DOI":"10.1073\/pnas.1006151107","article-title":"miRNA malfunction causes spinal motor neuron disease.","volume":"107","author":"Haramati","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"noi260007r4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2174\/1871527314666150116125506","article-title":"MicroRNAs: newcomers into the ALS picture.","volume":"14","author":"Volonte","year":"2015","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"3","key":"noi260007r5","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1007\/s12035-017-0537-z","article-title":"MicroRNA metabolism and dysregulation in amyotrophic lateral sclerosis.","volume":"55","author":"Rinchetti","year":"2018","journal-title":"Mol Neurobiol"},{"key":"noi260007r6","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3389\/fimmu.2017.01005","article-title":"Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications.","volume":"8","author":"Liu","year":"2017","journal-title":"Front Immunol"},{"key":"noi260007r7","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7070469","article-title":"Neuroinflammation and ALS: transcriptomic insights into molecular disease mechanisms and therapeutic targets.","volume":"2017","author":"Morello","year":"2017","journal-title":"Mediators Inflamm"},{"issue":"4","key":"noi260007r8","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1007\/s12035-017-0532-4","article-title":"Therapeutic strategies under development targeting inflammatory mechanisms in amyotrophic lateral sclerosis.","volume":"55","author":"Crisafulli","year":"2018","journal-title":"Mol Neurobiol"},{"issue":"4","key":"noi260007r9","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/s41380-023-02399-z","article-title":"Iron imbalance in neurodegeneration.","volume":"29","author":"Levi","year":"2024","journal-title":"Mol Psychiatry"},{"issue":"5","key":"noi260007r10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s10534-018-0126-2","article-title":"Oxidative stress and neurodegeneration: the involvement of iron.","volume":"31","author":"Carocci","year":"2018","journal-title":"Biometals"},{"issue":"1","key":"noi260007r11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40035-020-00228-9","article-title":"Aberrations of biochemical indicators in amyotrophic lateral sclerosis: a systematic review and meta-analysis.","volume":"10","author":"Cheng","year":"2021","journal-title":"Transl Neurodegener"},{"key":"noi260007r12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3389\/fneur.2020.00380","article-title":"Abnormal serum iron-status indicator changes in amyotrophic lateral sclerosis (ALS) patients: a meta-analysis.","volume":"11","author":"Wang","year":"2020","journal-title":"Front Neurol"},{"issue":"8","key":"noi260007r13","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/nbt.1481","article-title":"A small molecule enhances RNA interference and promotes microRNA processing.","volume":"26","author":"Shan","year":"2008","journal-title":"Nat Biotechnol"},{"issue":"10","key":"noi260007r14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185801","article-title":"A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein.","volume":"12","author":"Valianatos","year":"2017","journal-title":"PLoS One"},{"issue":"36","key":"noi260007r15","doi-asserted-by":"publisher","first-page":"22287","DOI":"10.1074\/jbc.M115.671222","article-title":"Nonantibiotic effects of fluoroquinolones in mammalian cells.","volume":"290","author":"Badal","year":"2015","journal-title":"J Biol Chem"},{"issue":"8","key":"noi260007r16","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1212\/WNL.58.8.1277","article-title":"Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients.","volume":"58","author":"Almer","year":"2002","journal-title":"Neurology"},{"key":"noi260007r17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jneuroim.2017.12.006","article-title":"Combination treatment of celecoxib and ciprofloxacin attenuates live S. aureus induced oxidative damage and inflammation in murine microglia via regulation of cytokine balance.","volume":"316","author":"Dey","year":"2018","journal-title":"J Neuroimmunol"},{"issue":"1","key":"noi260007r18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1128\/AAC.00735-10","article-title":"Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor.","volume":"55","author":"Kalle","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"noi260007r19","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/acn3.51174","article-title":"Efficacy of ciprofloxacin\/celecoxib combination in zebrafish models of amyotrophic lateral sclerosis.","volume":"7","author":"Goldshtein","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"noi260007r20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/ph18040524","article-title":"Elucidating the synergistic effect of the PrimeC combination for amyotrophic lateral sclerosis in human induced pluripotent stem cell-derived motor neurons and mouse models.","volume":"18","author":"Salomon-Zimri","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3-4","key":"noi260007r21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/21678421.2022.2119868","article-title":"Combination of ciprofloxacin\/celecoxib as a novel therapeutic strategy for ALS.","volume":"24","author":"Salomon-Zimri","year":"2023","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"5","key":"noi260007r22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/146608200300079536","article-title":"El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.","volume":"1","author":"Brooks","year":"2000","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"11","key":"noi260007r23","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1212\/WNL.0000000000012545","article-title":"Innovating clinical trials for amyotrophic lateral sclerosis: challenging the established order.","volume":"97","author":"van Eijk","year":"2021","journal-title":"Neurology"},{"issue":"3","key":"noi260007r25","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","article-title":"The nf-core framework for community-curated bioinformatics pipelines.","volume":"38","author":"Ewels","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"12","key":"noi260007r26","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"issue":"2","key":"noi260007r27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/mus.26106","article-title":"Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis.","volume":"58","author":"Raheja","year":"2018","journal-title":"Muscle Nerve"},{"key":"noi260007r28","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1106497","article-title":"Signature of miRNAs derived from the circulating exosomes of patients with amyotrophic lateral sclerosis.","volume":"15","author":"Cheng","year":"2023","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"noi260007r29","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.200116","article-title":"An miRNA fingerprint using neural-enriched extracellular vesicles from blood plasma: towards a biomarker for amyotrophic lateral sclerosis\/motor neuron disease.","volume":"10","author":"Banack","year":"2020","journal-title":"Open Biol"},{"issue":"11","key":"noi260007r30","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s41593-021-00936-z","article-title":"Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis.","volume":"24","author":"Magen","year":"2021","journal-title":"Nat Neurosci"},{"issue":"7","key":"noi260007r31","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1212\/WNL.0b013e318199049e","article-title":"\u201cDisease-modification\u201d trials in Parkinson disease: target populations, endpoints and study design.","volume":"72","author":"Rascol","year":"2009","journal-title":"Neurology"},{"issue":"13","key":"noi260007r32","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","article-title":"A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease.","volume":"361","author":"Olanow","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"noi260007r33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"noi260007r34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S1474-4422(18)30391-0","article-title":"Safety and efficacy of pridopidine in patients with Huntington\u2019s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.","volume":"18","author":"Reilmann","year":"2019","journal-title":"Lancet Neurol"},{"issue":"13","key":"noi260007r35","doi-asserted-by":"publisher","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","article-title":"Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.","volume":"95","author":"Hauser","year":"2020","journal-title":"Neurology"},{"key":"noi260007r24","unstructured":"TRICALS. Risk profile calculator. Accessed September 21, 2022. https:\/\/tricals.shinyapps.io\/risk-profile\/"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2846474\/jamaneurology_cudkowicz_2026_oi_260007_1778071471.07037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:00:28Z","timestamp":1778511628000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2846474"}},"subtitle":["The PARADIGM Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2026.0230","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}